Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.
Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the α4β2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. Achieve’s focus is to address the global smoking health epidemic by making cytisinicline widely available.
In RAUORA study, led by Dr. Natalie Walker – Associate Professor at the University of Auckland, cytisinicline-treaded subjects experienced significantly fewer side effects and were 55% more likely to quit smoking compared to those who received Chantix ®
Chantix® is a registered trademark of Pfizer Inc.